Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Abstract Background Metastatic castration-resistant prostate cancer remains a challenging condition to treat. Among the available therapeutic options, the androgen receptor signaling inhibitors abiraterone acetate plus prednisone (AA) and enzalutamide (Enza), are currently the most used first-line t...

Full description

Bibliographic Details
Main Authors: Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Valenca Bueno, Livia Maria Q. S. Andrade, Anna Patrikidou, Ricardo Pereira Mestre, Mikol Modesti, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini, the SPARTACUSS Investigators
Format: Article
Language:English
Published: BMC 2023-02-01
Series:Journal of Translational Medicine
Subjects:
Metastatic castration-resistant prostate cancer
Enzalutamide
Abiraterone acetate
Androgen receptor pathway inhibitors
Volume of disease
Metachronous metastases
Online Access:https://doi.org/10.1186/s12967-022-03861-2

Similar Items

Similar Items